Vilazodone

Vilazodone

Error creating thumbnail:

Vilazodone_synthesis01

Vilazodone is a pharmacological compound primarily recognized as a selective serotonin reuptake inhibitor (SSRI) with added properties as a partial serotonin receptor agonist. It is most commonly prescribed for the treatment of major depressive disorders.

Liver Safety

Extensive scrutiny into the safety of Vilazodone, particularly concerning the liver, has been undertaken. In studies conducted prior to its commercial release, vilazodone therapy was not correlated with a rise in serum aminotransferase levels, a common marker for liver health. Moreover, there is no evidence currently linking vilazodone to instances of clinically significant acute liver injury.

Mechanism of Action

Vilazodone operates predominantly as an SSRI, targeting the synaptic clefts in the Central Nervous System (CNS). By inhibiting the reuptake of serotonin, it results in elevated levels of this neurotransmitter in the brain, which is believed to be associated with its psychiatric benefits. Additionally, as a partial serotonin (5-HT1A) receptor agonist, vilazodone possibly enhances its antidepressant capabilities.

FDA Approval

The U.S. Food and Drug Administration (FDA) granted approval for the use of Vilazodone in the treatment of major depressive disorder in 2011. However, it's noteworthy that the clinical experience with vilazodone remains relatively limited compared to other SSRIs.

Brand Name

Vilazodone can be procured in the pharmaceutical market under the brand name Viibryd. It is accessible in tablet form in concentrations of 10, 20, and 40 mg.

Dosage and Administration

For adults initiating vilazodone therapy, a starting dose of 10 mg daily is recommended. Depending on the individual's response and tolerance, this can subsequently be escalated to a standard maintenance dose of 40 mg taken once daily.

Side Effects

Like all therapeutic compounds, vilazodone comes with potential side effects. Common and relatively benign symptoms reported include:

• Diarrhea
• Nausea
• Fatigue
• Drowsiness
• Headache
• Insomnia
• Weight gain
• Sexual dysfunction

In cases of overdose, patients may exhibit symptoms of the acute serotonin syndrome. Rarer, yet more severe potential adverse reactions encompass:

• Suicidal ideation and behavior
• Activation of manic symptoms
• Prolonged sexual dysfunction
• Hyponatremia
• Severe hypersensitivity reactions

See Also

• List of SSRIs
• Major depressive disorder
• Serotonin syndrome

The following are antidepressant subclasses and drugs

MAO Inhibitors Isocarboxazid, Phenelzine, Tranylcypromine

SNRIs Duloxetine, Levomilnacipran, Venlafaxine

SSRIs Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Vilazodone, Vortioxetine

Tricyclics Amitriptyline, Amoxapine, Clomipramine, Desipramine, Doxepin, Imipramine, Nortriptyline, Protriptyline, Trimipramine

Miscellaneous Bupropion, Flibanserin, Mirtazapine, Nefazodone, Trazodone

• Dailymed label info on Vilazodone
• FDA Vilazodone

Vilazodone Resources
Latest articles Most recent articles Ongoing trials	Wikipedia

Vilazodone Resources
Latest articles Most recent articles Ongoing trials	Wikipedia